More than 20,000 patients across 200 GP surgeries in England will be offered advanced blood tests designed to detect cancer at its earliest stages, as part of a new NHS trial to assess how well they perform in real-world conditions.
The tests identify signals in the blood to determine whether a patient needs further investigation for suspected cancer or whether the disease can be confidently ruled out. The aim is to detect cancer sooner through a simple blood test requested by a GP, while also reducing unnecessary hospital referrals for more invasive procedures.
Trial Details and Participating Companies
The trial, named STRIDE-RCT, will involve people aged 45 and over who visit their GP with abdominal symptoms such as persistent bloating or discomfort. They will be given the chance to try one of the tests.
The first companies involved are Proteotype (with the Enlighten test), Pinpoint AI (with the PinPoint test) and Mercy Bioanalytics (with the Halo test). Additional tests could be incorporated at a later stage.
How the Tests Work
The Enlighten test analyses patterns of circulating amino acid biomarkers in human plasma, then uses AI to assess the likelihood of a patient having breast, bowel, lung or prostate cancer. It is designed for individuals who may be experiencing unclear symptoms or who are known to face a heightened risk of cancer.
The Pinpoint AI test combines multiple weak cancer signals found in the blood to produce a single, more definitive result. It simultaneously analyses 32 biomarkers, measuring how they interact and their relationship to cancer risk. Research so far indicates it can detect signs of bowel, ovarian, lung, pancreatic, liver, bile duct and stomach cancer. Results are returned to the referring doctor using a red, amber, green system: green indicates low risk (rule-out), amber is average risk (continue standard assessment) and red is high risk (prioritise).
The Halo test analyses particles called single extracellular vesicles, which circulate at high levels in the blood even in early-stage cancer.
Official Reactions and Next Steps
Health minister James Frith told LBC Radio: "This is an exciting and world-first major trial for earlier diagnoses for abdominal cancers, which are notoriously hard to spot, very often because their symptoms can be misread as something other than cancer." He indicated that it could take between 18 and 24 months to establish whether any of the tests might be appropriate for a nationwide rollout.
Health Secretary Yvette Cooper said: "The earlier cancers are diagnosed, the more chance they can be successfully treated, and lives can be saved. Innovations like these are a key part of our National Cancer Plan, which will provide faster diagnosis, more effective treatment, and better care for every patient, while also investing in the trials and technology that offer hope of curing cancer for good."
Professor Peter Johnson, NHS national clinical director for cancer, said: "We are at the start of revolution in cancer diagnosis, and this trial will help us to find out whether blood tests can help GPs get the right patients to the right tests sooner, supporting earlier diagnosis when treatment is most likely to be successful."
Michelle Mitchell, chief executive of Cancer Research UK, said: "GPs have long needed better tools to help them navigate that uncertainty by identifying which patients require further testing and this trial in England is an important step towards addressing that need." The findings will be valuable in guiding further research, including whether these tests could be used in the NHS.